[an error occurred while processing this directive] | [an error occurred while processing this directive]
Significance of postoperative radiotherapy in treatment of stage T1-2N0M0 small-cell lung cancer
Liu Weishuai*,Zhao Lujun,Zhang Baozhong,Gong Linlin,Guan Yong,Wang Ping
*Department of Pain Relief,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center of Cancer,Tianjin Key Laboratory of Cancer Prevention and Therapy,Tianjin 300060,China
Abstract Objective To investigate the impact of postoperative radiotherapy (PORT) on the prognosis of early-stage small-cell lung cancer (SCLC). Methods The clinical data of 71 patients who were clinically diagnosed with stage T1-2N0M0 SCLC and underwent radical resection surgery in our hospital from 1997 to 2010 were retrospectively analyzed. Thirty-one patients received PORT, and fifty-five patients received preoperative or postoperative chemotherapy. The locoregional recurrence (LRR), distant metastasis, and overall survival (OS) rates were calculated using the Kaplan-Meier method. The log-rank test was used for survival difference analysis and univariate prognostic analysis. The multivariate prognostic analysis was made by the Cox regression model. Results The 5-year sample size was 32. The 5-year OS and LRR rates were 52% and 22%, respectively. PORT had no significant impact on OS rate (P=0.524). There were no significant differences in median OS and 5-year LRR rates between node-negative patients treated with and without PORT (47.3 vs. 96.8 months, P=0.561;39% vs. 23%, P=0.934). In the node-positive patients, patients treated with PORT had a significantly higher median OS rate and a significantly lower 5-year LRR rate than those treated without PORT (66.7 vs. 34.6 months, P=0.016;5% vs. 75%, P=0.004). The distant metastasis rate was 30% in all patients, and PORT had no significant impact on the distant metastasis rate (P=0.576). Conclusions PORT significantly reduces LRR rate and improves OS rate in node-positive patients with SCLC. However, it slightly reduces OS rate in node-negative patients. Therefore, PORT is recommended for node-positive patients with SCLC.
Liu Weishuai*,Zhao Lujun,Zhang Baozhong et al. Significance of postoperative radiotherapy in treatment of stage T1-2N0M0 small-cell lung cancer [J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 484-487.
Liu Weishuai*,Zhao Lujun,Zhang Baozhong et al. Significance of postoperative radiotherapy in treatment of stage T1-2N0M0 small-cell lung cancer [J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 484-487.
[1] Turrisi AT,Kim K,Blum R,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J].N Engl J Med,1999,340(4):265-271.DOI:10.1056/NEJM199901283400403. [2] Kalemkerian GP,Akerley W,Bogner P,et al. Small cell lung cancer[J].J Natl Compr Canc Netw,2013,11(1):78-98. [3] Goldstraw P,Crowley J,Chansky K,et al. The IASLC lung cancer staging project:proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours[J].J Thorac Oncol,2007,2(8):706-714. [4] Schreiber D,Rineer J,Weedon J,et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer:should its role be re-evaluated?[J].Cancer,2010,116(5):1350-1357.DOI:10.1002/cncr.24853. [5] Asamura H,Goya T,Koshiishi Y,et al. A Japanese Lung Cancer Registry study:prognosis of 13,010 resected lung cancers[J].J Thorac Oncol,2008,3(1):46-52.DOI:10.1097/JTO.0b013e31815e8577. [6] Varlotto JM,Recht A,Flickinger JC,et al. Lobectomy leads to optimal survival in early-stage small cell lung cancer:a retrospective analysis[J].J Thorac Cardiovasc Surg,2011,142(3):538-546.DOI:10.1016/j.jtcvs.2010.11.062. [7] Ju MH,Kim HR,Kim JB,et al. Surgical outcomes in small cell lung cancer[J].Korean J Thorac Cardiovasc Surg,2012,45(1):40-44.DOI:10.5090/kjtcs.2012.45.1.40. [8] Weksler B,Nason KS,Shende M,et al. Surgical resection should be considered for stage Ⅰ and Ⅱ small cell carcinoma of the lung[J].Ann Thorac Surg,2012,94(3):889-893.DOI:10.1016/j.athoracsur.2012.01.015. [9] Bischof M,Debus J,Herfarth K,et al. Surgery and chemotherapy for small cell lung cancer in stages Ⅰ－Ⅱ with or without radiotherapy[J].Strahlenther Onkol,2007,183(12):679-684.DOI:10.1007/s00066-007-1740-z. [10] Inoue M,Miyoshi S,Yasumitsu T,et al. Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University,Osaka,Japan[J].Ann Thorac Surg,2000,70(5):1615-1619. [11] Abedallaa N,Tremblay L,Baey C,et al. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma[J].J Thorac Oncol,2012,7(7):1179-1183.DOI:10.1097/JTO.0b013e3182572ead. [12] Gong LL,Wang QI,Zhao LJ,et al. Factors affecting the risk of brain metastasis in small cell lung cancer with surgery:is prophylactic cranial irradiation necessary for stage Ⅰ－Ⅲ disease?[J].Int J Radiat Oncol Biol Phys,2013,85(1):196-200.DOI:10.1016/j.ijrobp.2012.03.038.
2015, Vol. 24 
